Xeris Biopharma Holdings, Inc. (XERS) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $6.87 (-0.22%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 29, 2025 | Leland Gershell | Oppenheimer | $18.00 | +162.2% |
| Nov 11, 2024 | Oren Livnat | H.C. Wainwright | $6.60 | -3.9% |
| Oct 23, 2024 | Leland Gershell | Oppenheimer | $5.00 | -27.2% |
| May 10, 2024 | David Amsellem | Piper Sandler | $3.00 | -56.3% |
Top Analysts Covering XERS
XERS vs Sector & Market
| Metric | XERS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 2 | 8 | 19 |
| Target Upside | +27.5% | +11475.0% | +17.1% |
| P/E Ratio | 105.62 | 3.81 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $381M | $384M | $389M | 5 |
| 2027-03-31 | $105M | $108M | $111M | 2 |
| 2027-06-30 | $112M | $116M | $119M | 2 |
| 2027-09-30 | $121M | $125M | $128M | 2 |
| 2027-12-31 | $130M | $134M | $137M | 2 |
| 2028-03-31 | $121M | $125M | $128M | 1 |
| 2028-06-30 | $125M | $129M | $132M | 1 |
| 2028-09-30 | $130M | $134M | $137M | 1 |
| 2028-12-31 | $134M | $138M | $141M | 1 |
| 2029-12-31 | $595M | $608M | $628M | 5 |
| 2030-12-31 | $687M | $701M | $725M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.06 | $0.12 | $0.20 | 4 |
| 2027-03-31 | $0.04 | $0.04 | $0.04 | 2 |
| 2027-06-30 | $0.07 | $0.07 | $0.07 | 1 |
| 2027-09-30 | $0.09 | $0.10 | $0.10 | 1 |
| 2027-12-31 | $0.13 | $0.14 | $0.14 | 2 |
| 2028-03-31 | $0.09 | $0.09 | $0.09 | 3 |
| 2028-06-30 | $0.10 | $0.10 | $0.10 | 2 |
| 2028-09-30 | $0.11 | $0.11 | $0.11 | 2 |
| 2028-12-31 | $0.12 | $0.13 | $0.13 | 3 |
| 2029-12-31 | $0.87 | $0.89 | $0.93 | 1 |
| 2030-12-31 | $1.06 | $1.09 | $1.14 | 1 |
Frequently Asked Questions
What is the analyst consensus for XERS?
The consensus among 2 analysts covering Xeris Biopharma Holdings, Inc. (XERS) is Buy with an average price target of $9.00.
What is the highest price target for XERS?
The highest price target for XERS is $18.00, set by Leland Gershell at Oppenheimer on 2025-10-29.
What is the lowest price target for XERS?
The lowest price target for XERS is $3.00, set by David Amsellem at Piper Sandler on 2024-05-10.
How many analysts cover XERS?
2 analysts have issued ratings for Xeris Biopharma Holdings, Inc. in the past 12 months.
Is XERS a buy or sell right now?
Based on 2 analyst ratings, XERS has a consensus rating of Buy (2.00/5) with a +27.5% upside to the consensus target of $9.00.
What are the earnings estimates for XERS?
Analysts estimate XERS will report EPS of $0.12 for the period ending 2026-12-31, with revenue estimated at $384M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.